LifeSemantics‘s Canofy MD SCAI, an AI solution that detects skin cancer, has received approval from Korea’s Ministry of Food and Drug Safety, according to the Korean digital health company.

Canofy MD SCAI employs image processing technology based on convolutional neural networks to refine the classification of malignant and benign tumors. It identifies malignant melanoma, basal cell carcinoma, and squamous cell carcinoma, as well as benign tumors such as nevi, seborrheic keratoses, actinic keratoses, age spots, and lichen planus.

LifeSemantics aims to verify the safety, efficacy, and usability of Canofy MD SCAI in six medical institutions that include primary clinics and tertiary hospitals.